Our findings complement prior work that has demonstrated a role for CKB in promoting cell survival, migration, chemotaxis, and metastasis in hepatocellular carcinoma, pancreatic ductal adenocarcinoma, prostate cancer, osteosarcoma, and estrogen receptor–negative breast cancer (6, 11, 50, 51, 52). Here, ESR1 is linked to prostate cancer.